215 results on '"Baiges, Anna"'
Search Results
2. Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome
3. Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology
4. Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study
5. Persistent varices in cured patients: Understanding the role of hepatic venous pressure gradient
6. Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies
7. Porto-sinusoidal vascular disorder in chronic HBV: A significant coexistence not to be overlooked
8. Evolution of spontaneous portosystemic shunts over time and following aetiological intervention in patients with cirrhosis
9. Splanchnic vein thrombosis associated with SARS-CoV-2 infection: A VALDIG case–control study
10. Incidence and factors predictive of recurrent thrombosis in people with non-cirrhotic portal vein thrombosis
11. Non-invasive tests for clinically significant portal hypertension after HCV cure
12. The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study
13. Impact of SARS-CoV-2 Pandemic on Vascular Liver Diseases
14. Baveno VII – Renewing consensus in portal hypertension
15. Management of Liver Decompensation in Advanced Chronic Liver Disease: Ascites, Hyponatremia, and Gastroesophageal Variceal Bleeding
16. Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors
17. Co-expression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease
18. Liver Transplantation for Porto-Sinusoidal Vascular Liver Disorder: Long-term Outcome
19. Treatment of Acute Variceal Bleeding in 2021—When to Use Transjugular Intrahepatic Portosystemic Shunts?
20. Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis
21. Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data
22. Extensive splanchnic vein thrombosis after SARS-CoV-2 vaccination: A Vascular Liver Disease Group (VALDIG) initiative.
23. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension
24. Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis
25. Precision medicine in variceal bleeding: Are we there yet?
26. Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: The VALDIG Fonliver prospective cohort
27. Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis
28. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis
29. Timing Affects Measurement of Portal Pressure Gradient After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension
30. Nonendoscopic management of acute esophageal variceal bleeding
31. Early transjugular intrahepatic portosystemic shunt: When, how and in whom?
32. Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: A case-control study
33. Acute variceal bleeding: risk stratification and management (including TIPS)
34. Pharmacologic prevention of variceal bleeding and rebleeding
35. Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis
36. Endoscopic Hemostasis in Acute Esophageal Variceal Bleeding
37. THU-295 - Recent splanchnic vein thrombosis occurring during Sars-Cov-2 infection-The VALDIG study
38. Chapter 5 - Obstruction of the liver circulation
39. Non‐invasive candidate protein signature predicts hepatic venous pressure gradient reduction in cirrhotic patients after sustained virologic response.
40. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis
41. Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis.
42. SAT-123 Evaluation of portal hemodynamics after etiological factor removal and persistence of varices in patients with an HVPG
43. SAT-074 Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension. A randomized, double-blind clinical trial
44. OS-081 Portal vein recanalization in non-cirrhotic patients with portal vein occlusion: first results of a VALDIG study
45. The Prognostic Value of Hepatic Venous Pressure Gradient in Patients With Cirrhosis Is Highly Dependent on the Accuracy of the Technique
46. THU-308 - Chronic hepatitis B infection and porto-sinusoidal vascular disorder, a non-negligible coexistence
47. THU-290 - Efficacy and safety of vaccination againts SARS-CoV-2 in patients with vascular liver disease
48. FRI-499 - Liver elastography is a useful technique to assess the severity of liver congestion in patients with Budd-Chiari syndrome
49. OS-123-YI - Porto sinusoidal vascular liver disorder: natural history and long-term outcome
50. GS-003 - Rivaroxaban improves survival and decompensation in cirrhotic patients with moderate liver dysfunction. Double-blind, placebo-controlled trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.